Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2020

February 2020 | 106 pages | ID: J257C21C0B4EN
Global Markets Direct

Abstracts

Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2020, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline landscape.

Juvenile macular degeneration is a series of inherited eye disorders that affects children and young adults. The most common form of juvenile macular degeneration is Stargardt disease. Stargardt's disease is an inherited autosomal recessive syndrome. Signs and symptoms include blurry or fuzzy vision, dark, empty spots in the center of vision and difficulty reading or performing detail work. Risk factors include arteriosclerosis, hypercholesterolemia, smoking and hypertension.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 10 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology).
• The pipeline guide reviews pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Juvenile Macular Degeneration (Stargardt Disease) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Severe Acute Respiratory Syndrome (SARS) - Overview
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Development
Severe Acute Respiratory Syndrome (SARS) - Therapeutics Assessment
Severe Acute Respiratory Syndrome (SARS) - Companies Involved in Therapeutics Development
Severe Acute Respiratory Syndrome (SARS) - Drug Profiles
Severe Acute Respiratory Syndrome (SARS) - Dormant Projects
Severe Acute Respiratory Syndrome (SARS) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Acucela Inc, H1 2020
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alkeus Pharmaceuticals Inc, H1 2020
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Alpine Biotherapeutics Corp, H1 2020
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Applied Genetic Technologies Corp, H1 2020
Juvenile Macular Degeneration (Stargardt Disease) - Pipeline by Astellas Pharma Inc, H1 2020
Juvenile Macular Degeneration (Stargardt Disease) - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Juvenile Macular Degeneration (Stargardt Disease), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Acucela Inc
Alkeus Pharmaceuticals Inc
Alpine Biotherapeutics Corp
Applied Genetic Technologies Corp
Astellas Pharma Inc
Beam Therapeutics Inc
Biogen Inc
Biophytis SA
Cardax Inc
Copernicus Therapeutics Inc
Generation Bio Corp
Grupo Ferrer Internacional SA
Ichor Therapeutics Inc
IVERIC bio Inc
Katairo GmbH
Lin Bioscience Inc
Mediphage Bioceuticals Inc
ProQR Therapeutics NV
Sanofi
Spark Therapeutics Inc
Stargazer Pharmaceuticals Inc
Vision Medicines Inc
Wave Life Sciences Ltd